Læknablaðið - 15.10.2006, Qupperneq 36

FRÆÐIGREINAR / HRÖNUN AUGNBOTNA
Beaver Dam Eye Study. Am J Epidemiol 2002; 156:589-98.
78. Mitchell P, Wang JJ, Smith W, Leeder SR. Smoking and
the 5-year incidence of age-related maculopathy: the Blue
Mountains Eye Study. Arch Ophthalmol 2002; 120:1357-63.
79. Cruickshanks KJ, Klein R, Klein BE, Nondahl DM. Sunlight
and the 5-year incidence of early age-related maculopathy:
the Beaver Dam Eye Study. Arch Ophthalmol 2001; 119:246-
50.
80. Diaz MN, Frei B, Vita JA, Keaney JF, Jr. Antioxidants and
atherosclerotic heart disease. N Engl J Med 1997; 337: 408-
16.
81. Mares-Perlman JA, Klein R, Klein BE, Greger JL, Brady
WE, Palta M, et al. Association of zinc and antioxidant
nutrients with age-related maculopathy. Arch Ophthalmol
1996; 114:991-7.
82. Mares-Perlman JA, Fisher AI, Klein R, Palta M, Block G,
Millen AE, et al. Lutein and zeaxanthin in the diet and
serum and their relation to age-related maculopathy in the
third national health and nutrition examination survey. Am J
Epidemiol 2001; 153:424-32.
83. A randomized, placebo-controlled, clinical trial of high-dose
supplementation with vitamins C and E and beta carotene
for age-related cataract and vision loss: AREDS report no. 9.
Arch Ophthalmol 2001; 119:1439-52.
84. Smith W, Mitchell P, Leeder SR. Dietary fat and fish intake
and age-related maculopathy. Arch Ophthalmol 2000; 118:
401-4.
85. Remky A, Weber A, Arend O, Sponsel WE. Topical
dorzolamide increases pericentral visual function in age-
related maculopathy: pilot study findings with short-
wavelength automated perimetry. Acta Ophthalmol Scand
2005; 83:154-60.
86. Jonas JB. Intravitreal triamcinolone acetonide for treatment
of intraocular oedematous and neovascular diseases. Acta
Ophthalmol Scand 2005; 83:645-63.
87. Degenring RF, Jonas JB. Photodynamic therapy in
combination with intravitreal triamcinolone for myopic
choroidal neovascularization. Acta Ophthalmol Scand 2005;
83:621.
88. Gustavsson C, Agardh E. Macular infarction after
transpupillary thermotherapy for subfoveal choroidal
neovascularization in age-related macular degeneration
- a possible association with systemic inflammatory disease?
Acta Ophthalmol Scand 2004; 82:100-2.
89. Frennesson CI. Photodynamic therapy with verteporfin
in patients with age-related macular degeneration and
juxtafoveal choroidal neovascularization. Acta Ophthalmol
Scand 2004; 82:651-5.
90. Frennesson CI, Nilsson SE. Encouraging results of
photodynamic therapy with Visudyne in a clinical patient
material of age-related macular degeneration. Acta
Ophthalmol Scand 2004; 82:645-50.
91. la Cour M. Photodynamic therapy for AMD: smaller is
better! Acta Ophthalmol Scand 2004; 82:641-2.
92. Wirostko E, Wirostko WJ, Wirostko BM. Age-related
macular degeneration is an inflammatory disease possibly
treatable with minocycline. Acta Ophthalmol Scand 2004; 82:
243-4.
93. Tlie effect of five-year zinc supplementation on serum zinc,
serum cholesterol and hematocrit in persons randomly
assigned to treatment group in the age-related eye disease
study: AREDS Report No. 7. J Nutr 2002; 132:697-702.
94. A randomized, placebo-controlled, clinical trial of high-dose
supplementation with vitamins C and E, beta carotene, and
zinc for age-related macular degeneration and vision loss:
AREDS report no. 8. Arch Ophthalmol 2001; 119:1417-36.
95. The effect of vitamin E and beta carotene on the incidence of
lung cancer and other cancers in male smokers. The Alpha-
Tocopherol, Beta Carotene Cancer Prevention Study Group.
N Engl J Med 1994; 330:1029-35.
96. Omenn GS, Goodman GE,Thornquist MD, Balmes J, Cullen
MR, Glass A, et al. Effects of a combination of beta carotene
and vitamin A on lung cancer and cardiovascular disease. N
Engl J Med 1996; 334:1150-5.
97. Laatikainen L. The fluorescein angiography revolution:
a breakthrough with sustained impact. Acta Ophthalmol
Scand 2004; 82:381-92.
98. KumarA,PrakashG,Singh RP.Transpupillary thermotherapy
for idiopathic subfoveal choroidal neovascularization. Acta
Ophthalmol Scand 2004; 82:205-8.
99. Klosinski ST. Reading with AMD. In: Holz FGP, Spaide
D, Bird RF,AC. editor. Age-ralated macular degeneration.
Berlin: Springer; 2003:120-6.
100. Delyfer MN, Rougier MB, Fourmaux E, Cousin P,
Korobelnik JF. Laser photocoagulation for choroidal
neovascular membrane associated with optic disc drusen.
Acta Ophthalmol Scand 2004; 82:236-8.
101. Anti-vascular endothelial growth factor therapy for subfoveal
choroidal neovascularization secondary to age-related
macular degeneration: phase II study results. Ophthalmology
2003; 110:979-86.
102. Kvanta A. Ocular angiogenesis: the role of growth factors.
Acta Ophthalmol Scand 2006; 84:282-8.
103. Björnsson G. Blinda á íslandi, nokkrar athuganir á blindu
fólki í árslok 1950. Læknablaðið 1954; 38:65-79.
104. Bjornsson G. Prevalence and causes of blindness in
Iceland, with special reference to glaucoma simplex. Am J
Ophthalmol 1955;39:202-8.
105. Björnsson G. Blindness in Iceland. A review of legally blind
persons in Iceland 1. dec. 1979. Acta Ophthalmol 1981; 59:
921-7.
106. Björnsson G.Augnhagur Borgfirðinga. Yfirlit umsjón,sjónlag
og algengustu augnsjúkdóma í Borgarneslæknisumdæmi.
Læknaneminn 1978;31:5-18.
107. Jónasson F, Þórðarson K. Augnhagur 751 Austfirðings 43ja
ára og eldri á árunum 1980-1984. Algengi augnsjúkdóma,
sjónskerðingar og blindu. Læknablaðið 1987;73:205-13.
108. Jonasson F, Tliordarson K. Prevalence of ocular disease and
blindness in a rural area in the eastern region of Iceland
during 1980 through 1984. Acta Ophthalmol Suppl 1987; 182:
40-3.
109. Ólafsdóttir Ó, Gíslason I, Jónasson F, Stefánsson E.
Ellihrörnun í augnbotnum. Læknablaðið 1992; 78:118-24.
110. RohrschneiderK,BruderI,BlankenagelA.[Ophthalmo!ogical
rehabilitation - experience at the University Eye Hospital
Heidelberg]. Ophthalmologe 1999; 96:611-6.
111. Rohrschneider K, Kiel R, Pavlovska V, Blankenagel
A. [Satisfaction with low vision aids]. Klin Monatsbl
Augenheilkd 2002; 219:507-11.
112. Eperjesi F, Fowler CW, Evans BJ. The effects of coloured
light filter overlays on reading rates in age-related macular
degeneration. Acta Ophthalmol Scand 2004; 82:695-700.
113. Nilsson SE. Are there advantages in implanting a yellow IOL
to reduce the risk of AMD? Acta Ophthalmol Scand 2004;
82:123-5.
114. Bischoff P. Long-term results of Iow vision rehabilitation in
age-related macular degeneration. Doc Ophthalmol 1995; 89:
305-11.
115. Miller D,W. Evaluation ofan adaptive SkillsTraining Program
for Patients with advanced bilateral AMD. (Abstract). IAge-
Related Macular Degeneration Pathogenesis andTreatment;
2003 September 4-6; Baden-Baden Germany; 2003:7.
116. Rovner BW, Zisselman PM, Shmuely-Dulitzki Y. Depression
and disability in older people with impaired vision: a follow-
up study. J Am Geriatr Soc 1996; 44:181-4.
117. Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown
SI. The psychosocial impact of macular degeneration. Arch
Ophthalmol 1998; 116:514-20.
118. Brody BL, Roch-Levecq AC, Gamst AC, Maclean K, Kaplan
RM, Brown SI. Self-management of age-related macular
degeneration and quality of life: a randomized controlled
trial. Arch Ophthalmol 2002; 120:1477-83.
119. Mangione CM, Gutierrez PR, Lowe G, Orav EJ, Seddon JM.
Influence of age-related maculopathy on visual functioning
and health-related quality of life. Am J Ophthalmol 1999;
128:45-53.
120. Hazel CA, Petre KL, Armstrong RA, Benson MT. Frost NA.
Visual function and subjective quality of life compared in
subjects with acquired macular disease. Invest Ophthalmol
Vis Sci 2000; 41:1309-15.
121. Brown MM, Brown GC, Sharma S, Busbee B. Quality of life
associated with visual loss: a time tradeoff utility analysis
comparison with medical health states. Ophthalmology 2003;
110:1076-81.
122. Kelly SP, Edwards R, Elton P, Mitchell P. Age related macular
degeneration: smoking entails major risk of blindness. BMJ
2003; 326:1458-9.
123. Heilbrigðisáætlun til ársins 2010. Langtímamarkmið í heil-
brigðismálum. Heilbrigðis- og tryggingamálaráðuneytið;
Reykjavík 2001.
696 Læknablaðið 2006/92